Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a solution for injection for intravenous and subcutaneous use. It treats and prevents thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and acute coronary syndrome in at‑risk patients.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Enoxaparin Sodium is a low molecular weight heparin used to prevent and treat thromboembolic conditions.

- Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in surgical or immobilized patients. - Deep vein thrombosis (DVT) treatment: facilitates clot resolution in acute DVT. - Pulmonary embolism (PE) prevention and treatment: reduces risk of embolic events in at‑risk individuals. - Acute coronary syndrome (ACS) anticoagulation: provides antithrombotic protection during acute coronary events. - Thromboembolic prophylaxis in immobilized patients: lowers incidence of venous thromboembolism during prolonged immobility.

Enoxaparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: erythema, pain, or bruising at the administration site. - Minor bleeding: epistaxis, gum bleeding, or easy bruising. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Major hemorrhage: internal bleeding requiring medical intervention. - Thrombocytopenia: significant drop in platelet count, potentially leading to bleeding. - Elevated liver enzymes: abnormal hepatic function tests. - Allergic reactions: anaphylaxis or severe hypersensitivity.

Before using Ledraxen, consider the following safety measures.

- Renal impairment: adjust dose or avoid use in severe renal dysfunction. - Pregnancy: category B, use only if benefit outweighs risk. - Concomitant anticoagulants: avoid simultaneous use with other anticoagulants unless directed. - Recent surgery or trauma: assess bleeding risk before administration. - Spinal/epidural procedures: discontinue before neuraxial anesthesia to reduce hematoma risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Warfarin: combined use markedly increases bleeding risk. - Direct thrombin inhibitors (e.g., dabigatran): additive anticoagulant effect. - Antiplatelet agents (e.g., clopidogrel, aspirin) at high doses: heightened hemorrhage potential.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding. - Heparin products: overlapping anticoagulant activity. - Certain antibiotics (e.g., vancomycin): may potentiate anticoagulant effect.